Method for Treating Alzheimer's Disease
AssigneeBiogen International Neuroscience GmbH
InventorsJames L. Ferrero, Leslie Lugene Williams, Jeffrey Joseph Sevigny
Life of this patent
Estimating the term…
Abstract
A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
Claims35
A method for treatment of a human patient for Alzheimer's disease (AD), comprising:
- sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody in increasing amounts over a period of time to the patient, wherein, multiple doses of 1 mg/kg, 3 mg/kg, 6 mg/kg, and/or 10 mg/kg of body weight of the patient are administered to the patient at periodic intervals, optionally wherein the periodic intervals are about 4 weeks, optionally wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and
- (1) the VH comprises a first complementarity determining region (VHCDR1) with the amino acid sequence of SEQ ID NO:3, a VHCDR2 with the amino acid sequence of SEQ ID NO:4, and a VHCDR3 with the amino acid sequences of SEQ ID NO:5, and the VL comprises a VLCDR1 with the amino acid sequence of SEQ ID NO:6, a VLCDR2 with the amino acid sequence of SEQ ID NO:7, and a VLCDR3 with the amino acid sequence of SEQ ID NO:8, and
- (2) the antibody further comprises a human IgG1 constant region,
- further optionally wherein the antibody comprises the VH comprising the amino acid sequence of SEQ ID NO:1 and the VL comprising the amino acid sequence of SEQ ID NO:2.
-5. (canceled)
-10. (canceled)
-15. (canceled)
-18. (canceled)
-22. (canceled)
-27. (canceled)
A method for treatment of a human patient for Alzheimer's disease (AD), comprising:
- administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody over a period of time to the patient,
- wherein the patient is
- (a) n ApoE4 carrier and the monoclonal antibody is administered in an effective amount of 1 mg/kg or 3 mg/kg of the patient's body weight;
- or
- (b) an ApoE4 non-carrier and the antibody is administered in an effective amount of 3 mg/kg or 6 mg/kg or 10 mg/kg of the patient's body weight,
- optionally wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and
- (1) the VH comprises a first complementarity determining region (VHCDR1) with the amino acid sequence SEQ ID NO:3, a VHCDR2 with the amino acid sequence SEQ ID NO:4, and a VHCDR3 with the amino acid sequences SEQ ID NO:5, and the VL comprises a VLCDR1 with the amino acid sequence SEQ ID NO:6, a VLCDR2 with the amino acid sequence SEQ ID NO:7, and a VLCDR3 with the amino acid sequence SEQ ID NO:8, and
- (2) the antibody further comprises a human IgG1 constant region,
- further optionally wherein the antibody comprises the VH comprising the amino acid sequence of SEQ ID NO:1 and the VL comprising the amino acid sequence of SEQ ID NO:2.
-31. (canceled)
-34. (canceled)
-37. (canceled)
-40. (canceled)
(canceled)
-49. (canceled)
(canceled)
(canceled)
-68. (canceled)
Dependencies are inferred from the claim text.